Anthem Biosciences Q4 Results 2026 Preview, Earnings Estimates & Outlook
- March 24, 2026
- Posted by: Neeraj Pandey
- Category: News
Anthem Biosciences latest news: Anthem Biosciences Q4 FY26 results date is all set to be announced soon and most investors are awaiting it. Professionals are expecting an increase in revenue due to higher sales and a significant rise in PAT. Anthem Biosciences was listed on the National Stock Exchange (NSE) on 21-Jul-2025. Anthem Biosciences share has its face value of 2 per share, and its NSE symbol is ANTHEM. The company operates in the Healthcare sector and primarily belongs to the Biotechnology & CRAMS industry.
Anthem Biosciences Q4 Results 2026 Preview
- Anthem Biosciences Q4 FY26 revenue is expected to be around Strong Growth Expected, representing a 17-23% YoY increase compared to the same quarter last year.
- Profit After Tax, or PAT, is projected to rise 19-26% YoY.
- EBITDA to rise 18-24%.
- Anthem Biosciences is expected to show Strong Growth Expected in its revenue.
Click and Sign Up to Get Live Updates on Q4 Results
Anthem Biosciences Share Performance
- Over the past six months, Anthem Biosciences share price has Up by 30% to 644.75.
- Moreover, over the past year, the stock has Up by 52%
- Despite this weak short-term performance, Anthem Biosciences stock has delivered a financially sound 260% return over the past 5 years.
- As of today, 20-03-2026, the Anthem Biosciences share price is trading at 644.75 per share.
Key Factors to Watch for Anthem Biosciences Q4 Results FY26
- Revenue Growth & Segment Performance – Focus on topline growth in the Biotechnology & CRAMS industry within the Healthcare sector.
- Occupancy Levels & Seat Expansion – Monitor operational expansion and capacity utilisation trends.
- Profitability & Margin Trends – Track EBITDA and PAT margins to evaluate cost control and operating efficiency.
- Order Book & New Client Wins – Watch for updates on new contracts, partnerships, and long-term deals.
- Balance Sheet & Cash Flow Position – Review debt levels, working capital management, and operating cash flows for financial stability.
Visit Univest app or website to check more Anthem Biosciences latest news to make an informed investment decision.
About Anthem Biosciences
Anthem Biosciences is a biotechnology and pharmaceutical research company offering contract research manufacturing and drug discovery services to global pharmaceutical firms.
Visit Univest app or website to check more Anthem Biosciences latest news to make an informed investment decision.
Final Thoughts
Anthem Biosciences is gear up to announce its Q4 FY26 results. Analysts expect 17-23% revenue growth, a 19-26% rise in PAT, and a 18-24% rise in EBITDA. Anthem Biosciences focuses on revenue growth from order execution, margin improvement, a strong order book, and management.
Stay informed with Univest blogs to get real-time updates on Anthem Biosciences Q4 results FY26.
Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.
Recent Articles
AMD Industries Q4 Results Preview: Earnings Growth, Key Expectations & Outlook
Ambika Cotton Mills Q4 Results Preview: Earnings Growth, Key Expectations & Outlook
Amagi Q4 Results Preview: Earnings Growth, Key Expectations & Outlook
Alphageo Q4 Results Preview: Earnings Growth, Key Expectations & Outlook
Almondz Global Q4 Results Preview: Earnings Growth, Key Expectations & Outlook
